What do these trial results mean in practical terms
We're proud to be Serena's care partner, and even prouder to stand with her as she inspires people nationwide to reach their health goals." This announcement builds on Ro's mission to fight for patients and expand access to GLP-1 treatment through online doctor visits, personalized treatment plans, insurance coordination, education, and ongoing support
sulfonylureas, meglitinides), liraglutide increases the risk of hypoglycemia
I also cant talk about GLP-1s without acknowledging this truth: Access to obesity treatment is deeply unequal
Clinical trial data from the NEJM Phase 2 study showed that gastrointestinal events were predominantly mild to moderate, occurred primarily during dose escalation, and were partially mitigated by starting at 2mg rather than 4mg
GLP-1 Receptor Agonists and Noncardiometabolic Outcomes